{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:06:19Z","timestamp":1756339579948,"version":"3.44.0"},"reference-count":22,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,11,3]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>A man in his 60\u2009s with a history of actinic keratosis (AK) and relapsed IgG kappa multiple myeloma (MM) recently received VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) chemotherapy and presented with numerous haemorrhagic, scaly lesions on his scalp and face. He also had sepsis from methicillin-sensitive <jats:italic>Staphylococcus aureus<\/jats:italic> (MSSA) bacteraemia. Since the lesions were only present in the areas of pre-existing AK, a diagnosis of inflammation of AK secondary to chemotherapy was made. Sepsis was treated with appropriate antibiotics, and inflammation of AK was managed with topical steroids, leading to complete recovery.<\/jats:p>","DOI":"10.1136\/bcr-2023-256024","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:40:30Z","timestamp":1700570430000},"page":"e256024","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammation of actinic keratosis from chemotherapy in a relapsed multiple myeloma patient"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0724-0766","authenticated-orcid":false,"given":"Abdul Moiz","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarec","family":"Micho Ulbeh","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, Detroit Medical Center\/Wayne State University, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Zonder","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wayne State University, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"2025082711294119000_16.11.e256024.1","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-022-00682-3","article-title":"Correction to: a review of existing therapies for actinic keratosis: current status and future directions","volume":"23","author":"Del Regno","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2025082711294119000_16.11.e256024.2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ijd.14147","article-title":"Actinic keratosis - review for clinical practice","volume":"58","author":"de Oliveira","year":"2019","journal-title":"Int J Dermatol"},{"key":"2025082711294119000_16.11.e256024.3","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103340"},{"key":"2025082711294119000_16.11.e256024.4","doi-asserted-by":"crossref","DOI":"10.5070\/D33S83X36N","article-title":"Capecitabine induced inflammation of actinic keratoses","volume":"13","author":"Krathen","year":"2007","journal-title":"Dermatol Online J"},{"key":"2025082711294119000_16.11.e256024.5","doi-asserted-by":"crossref","DOI":"10.4076\/1757-1626-2-6946","article-title":"Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report","volume":"2","author":"Makdsi","year":"2009","journal-title":"Cases J"},{"key":"2025082711294119000_16.11.e256024.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(87)70189-3"},{"key":"2025082711294119000_16.11.e256024.7","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-209925","article-title":"Inflammation of actinic keratoses during paclitaxel chemotherapy","volume":"2015","author":"Ali","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2025082711294119000_16.11.e256024.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70488-3"},{"key":"2025082711294119000_16.11.e256024.9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025082711294119000_16.11.e256024.10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s13555-014-0049-y","article-title":"Actinic keratosis: rationale and management","volume":"4","author":"Dodds","year":"2014","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025082711294119000_16.11.e256024.11","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/ced.15332","article-title":"Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies","volume":"47","author":"Seervai","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2025082711294119000_16.11.e256024.12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/cup.14327","article-title":"The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy","volume":"50","author":"Seervai","year":"2023","journal-title":"J Cutan Pathol"},{"key":"2025082711294119000_16.11.e256024.13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ad.2017.08.015","article-title":"Inflammation of actinic keratosis during panitumumab therapy","volume":"109","author":"Escudero-G\u00f3ngora","year":"2018","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"2025082711294119000_16.11.e256024.14","first-page":"581","article-title":"Erlotinib-responsive actinic keratoses","volume":"18","author":"Hermanns","year":"2007","journal-title":"Oncol Rep"},{"key":"2025082711294119000_16.11.e256024.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2006.02223.x"},{"key":"2025082711294119000_16.11.e256024.16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000367959","article-title":"Dysregulation of epidermal growth factor receptor in actinic keratosis and squamous cell carcinoma","volume":"46","author":"Joseph","year":"2015","journal-title":"Curr Probl Dermatol"},{"key":"2025082711294119000_16.11.e256024.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2019.10.004"},{"key":"2025082711294119000_16.11.e256024.18","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1080\/09546634.2022.2131298","article-title":"Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis","volume":"33","author":"\u0160uler Baglama","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025082711294119000_16.11.e256024.19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaad.2005.11.1100","article-title":"Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment","volume":"55","author":"Peramiquel","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2025082711294119000_16.11.e256024.20","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.3.367"},{"key":"2025082711294119000_16.11.e256024.21","doi-asserted-by":"crossref","DOI":"10.5070\/D3243038616","article-title":"Temozolomide-induced inflammation of disseminated superficial Actinic Porokeratosis","volume":"24","author":"Lee","year":"2018","journal-title":"Dermatol Online J"},{"key":"2025082711294119000_16.11.e256024.22","doi-asserted-by":"crossref","unstructured":"Lam J , Ellis SR , Sivamani RK . Inflamed actinic keratoses associated with Pemetrexed and carboplatin therapy. Dermatol Online J 2017;23.","DOI":"10.5070\/D32310037009"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:29:49Z","timestamp":1756319389000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,21]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/bcr-2023-256024"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256024","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}